Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives
World Journal of Gastroenterology · 14.07.2026 · 32 (26)
DOI: 10.3748/wjg.116530 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.07.2026. Verfasst von Hou-Shu Tu und 3 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
Helicobacter pylori infection remains a major global health challenge, contributing to chronic gastritis, peptic ulcer disease, and gastric cancer. Rising antimicrobial resistance, host genetic variability, and inconsistent patient adherence have limited the effectiveness of conventional proton pump inhibitor-based eradication regimens. Vonoprazan-amoxicillin (VPZ-AMO) dual therapy is a promising first-line alternative, with high eradication rates, favorable tolerability, and simplified antibiotic exposure demonstrated in multicenter trials across Asia. Evidence suggests that VPZ-AMO dual therapy may outperform traditional proton pump inhibitor-based triple or bismuth quadruple therapies, particularly in populations with high clarithromycin resistance. However, important questions remain regarding its generalizability, optimal dosing, host pharmacogenetic effects, and potential long-term impacts on the gut microbiota. This opinion review summarizes current clinical evidence, highlights unresolved controversies, and outlines future research priorities, including multicenter validation, host factor-guided therapy, microbiome monitoring, and dosing optimization. By integrating these elements into a structured, sequential framework, VPZ-AMO dual therapy is presented as a safe, effective, and adaptable regimen, with substantial potential to improve Helicobacter pylori management and reduce the global burden of associated gastrointestinal diseases.
Zitieren
APA
Tu, H., Chen, M., Hong, J., & He, L. (2026). Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives. World Journal of Gastroenterology, 32(26). https://doi.org/10.3748/wjg.116530
Vancouver
Tu H, Chen M, Hong J, He L. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives. World Journal of Gastroenterology. 2026;32(26). doi:10.3748/wjg.116530
BibTeX
@article{Tu2026,
author = {Tu, Hou-Shu and Chen, Meng-Lin and Hong, Jing and He, Ling},
title = {Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {26},
doi = {10.3748/wjg.116530}
}
EUVIMED